Prediction: This Beaten-Down Stock Could Double in The Next 5 Years

Shares of CRISPR Therapeutics have lost momentum in recent years.
The company's lone marketed product isn't generating much revenue yet.
That should change over time, and the biotech could notch further clinical wins.
10 stocks we like better than CRISPR Therapeutics ›
Despite making significant clinical progress, CRISPR Therapeutics (NASDAQ: CRSP) has been struggling financially in the past three years. The company's shares are down by 24% over this period, while the S&P 500 has gained 41%. The gene-editing specialist has, no doubt, faced some headwinds.
However, important catalysts could double its stock price by 2030. For those keeping score at home, that would amount to a compound annual growth rate of about 14.9%, well above the market's historical average returns.
CRISPR Therapeutics' focus on gene editing has some advantages and disadvantages. On the one hand, its revolutionary techniques can allow researchers to create therapies for otherwise untreatable (or difficult-to-treat) conditions. CRISPR proved as much when it created and developed Casgevy, a one-time treatment that provides a functional cure for two genetic blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia. CRISPR shares the rights to Casgevy together with Vertex Pharmaceuticals.
On the other hand, ex vivo gene-editing treatments are complex to manufacture and administer. The process involves collecting the patient's cells, editing their genes, and reinserting them into the patient.
That's why, despite being approved since late 2023, Casgevy isn't meaningfully contributing to CRISPR Therapeutics' financial results yet. But it will eventually, and at its peak, is almost certain to far exceed the $1 billion per year in sales that is the milestone for blockbuster status. There are few competing treatments for sickle cell disease and transfusion-dependent beta-thalassemia, even in the U.S. The competitive landscape looks even better for CRISPR and Vertex in several countries in the Middle East, where they have received approvals for this product.
Overall, the two estimate an addressable market of 58,000 patients in the regions they are targeting. At $2.2 million per treatment course in the U.S., the opportunity looks massive. It might take time to get there, but expect CRISPR Therapeutics' sales to grow at a good clip once money starts rolling in from Casgevy, and that should happen well before the end of the decade.
Casgevy's slow uptake is one reason CRISPR Therapeutics stock has not performed well in recent years. Another is that clinical progress often drives the performance of small biotechs with few or no products on the market. Some investors take their profits and leave once they achieve significant clinical and regulatory milestones.
That's what happened here. CRISPR Therapeutics' shares skyrocketed in the five years following its 2016 IPO, a period during which it more than doubled.
CRSP data by YCharts
Though it has experienced a significant pullback since 2021, CRISPR Therapeutics could bounce back as it shows substantial pipeline progress while making commercial headway with Casgevy.
The company is working on several promising candidates for which it could release data readouts as early as this year. They include CTX112 and CTX131, two potential cancer medicines. The former received the Regenerative Medicine Advanced Therapy designation from the Food and Drug Administration, a sign that it has shown promising clinical evidence in treating a serious condition.
CRISPR Therapeutics should also release data from an ongoing clinical trial for CTX320, a medicine being developed to lower lipoprotein(a) levels, which can cause a range of cardiovascular problems when too high. These programs and others -- such as CRISPR's investigational functional cure for type 1 diabetes -- could make significant headway in the next five years.
They might not all pan out, but even a 50% success rate in getting products to market, after the smashing success it saw by laser-focusing on Casgevy, would be a significant win for the company. In the meantime, a series of clinical wins could eventually jolt the company's shares.
Of course, there is the possibility that the biotech will run into severe setbacks, and given that it only has one product on the market and remains unprofitable for now, that could send the stock down even further. CRISPR Therapeutics carries above-average risk as an investment, but for those comfortable with the volatility, it is worth initiating a small position in the stock -- it could deliver monster returns in the next five years.
Before you buy stock in CRISPR Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $642,582!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $829,879!*
Now, it's worth noting Stock Advisor's total average return is 975% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 12, 2025
Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.
Prediction: This Beaten-Down Stock Could Double in The Next 5 Years was originally published by The Motley Fool

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNBC

15 minutes ago

• CNBC

The Israel-Iran conflict and the other big thing that drove the stock market this week

It's been a tense and dynamic week for the world at large. The market action on Wall Street over the past four sessions was been anything but that. For the week, the S & P 500 lost 0.15%, the tech-heavy Nasdaq ticked up 0.21%, and the Dow Jones Industrial Average was basically flat, up a mere 0.02%. Beneath the surface, though, there was plenty of news for investors to digest. Here's a closer look at the biggest market themes during the holiday-shortened trading week. 1. Geopolitics: The major news story was — and still is — the intensifying war between Israel and Iran. The big question on everyone's mind is whether the U.S. will get involved. As of Friday, reports indicate that while President Donald Trump is actively reviewing options to attack Iran, nothing has been authorized. The White House has said Trump he will make a decision in the "next two weeks". As a result of the Israel-Iran conflict, investors spent the week keeping an extra close eye on the movement in safe-haven assets like gold and the dollar, as well as risk assets such as oil. Gold prices pulled back this week after their initial spike last Friday, which is when Israel's first attack on Iranian nuclear infrastructure jolted markets. The U.S. dollar index , meanwhile, strengthened this week but still remains near multiyear lows. Oil rose again for the week, with international benchmark Brent crude climbing nearly 4%. For those looking to gauge what the market thinks will happen with Iran, look to oil. The commodity is currently acting as something of proxy on the odds of the conflict intensifying and America directly entering the fray. 2. Fed updates: The other big theme of the week centered on the health of the U.S. economy in the lead up to Wednesday afternoon, when we got the Federal Reserve's latest interest rate decision and revised economic projections. Ultimately, the Fed kept its benchmark lending rate unchanged on Wednesday following its two-day policy meeting. The decision followed lackluster updates on the state of the consumer and the housing market , along with lower-than-expected inflation readings the week prior. As we outlined earlier this week , the Fed is in a tough spot when it comes to abiding by its dual mandate of ensuring price stability and low unemployment. The state of play requires nuance. On the one hand, there is evidence in support of rate cuts, namely some cracks in the consumer — even if the consumer has remained largely and impressively resilient — and the Fed's own updated outlook for lower real GDP growth and higher unemployment this year. On the other hand, the Fed is now expecting higher inflation this year than it did in March, which would support the need for higher interest rates. Given these dueling dynamics and the uncertainty around tariff impacts, the central bank's decision to keep interest rates steady makes sense. While the Fed certainly doesn't want to wait too long and make the same mistake we saw coming out of the Covid-19 pandemic, we must acknowledge that the causes of a potential rebound in inflation are different this time around. Tariffs will likely push up prices, but that may be a one-time increase, as opposed to the sustained inflation we saw exiting the pandemic, which was driven by massive supply chain disruptions and shifts in consumer behavior. As a result, we believe the apparent bias to be more worried about the job market and overall economic growth — and therefore cut rates later this year — makes sense, too. Indeed, the Fed's updated projections still pencil in two rate cuts in 2025, the same as in March despite the aforementioned revisions to its inflation and growth outlook. Fed Governor Christopher Waller made the case Friday that the cuts should start as early as July, arguing that the inflation risk posed by tariffs is not significant and ensuring resiliency in the labor market should be a higher priority. Waller's argument is basically that it's better to move now than wait for a jump in unemployment. Our biggest focus at the Club is staying nimble, given the highly volatile nature of geopolitics at the moment. No doubt, rate decisions are important to think about, but they're only one small part of the investing puzzle to navigate each day. For this reason, we continue to focus more on individual company fundamentals and industry trends rather than higher-level dynamics, important as they are to shaping our worldview. Cybersecurity stocks are one example that we highlighted this week. Another example would be the news we got from Club names Meta Platforms and Amazon this week on their artificial intelligence efforts. We think the implications that AI will have on the cost structures, revenue opportunities and efficiency gains should weigh far more heavily in the minds' of long-term investors than whether the Fed will cut in July or September. (Jim Cramer's Charitable Trust is long META, AMZN. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

Yahoo

39 minutes ago

• Yahoo

1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late

Applied Materials stock is in rebound mode. Even better, it still trades at an attractive valuation. The semiconductor equipment supplier expects stronger growth in the future due to increased spending by chipmakers and foundries. Applied Materials stock could deliver terrific gains going forward thanks to favorable end-market developments. 10 stocks we like better than Applied Materials › Share prices of Applied Materials (NASDAQ: AMAT) have jumped impressively from the 52-week lows they hit just over two months ago, gaining 31% in a short time on the back of the broader rally in the tech-laden Nasdaq Composite index that has clocked solid gains of 25% during the same period. What's worth noting is that investors shrugged off Applied Materials' mixed fiscal 2025 second-quarter results (for the three months ended April 27), which were released on May 15. The semiconductor equipment supplier reported robust growth in sales and earnings for the quarter, but its top line was a tad lighter than expected. The company's outlook for the current quarter followed a similar pattern. However, savvy investors would do well to note that Applied Materials' results and guidance were resilient at a time when the tariff-fueled turmoil and the restrictions on sales of semiconductor equipment to China are turning out to be headwinds for the company. Let's take a look at the factors that could help Applied Materials stock maintain its momentum on the market. Applied Materials reported year-over-year growth of 7% in its revenue in the previous quarter, while its non-GAAP earnings per share (EPS) increased at a faster pace of 14%. A quarter of its revenue came from sales of semiconductor manufacturing equipment to China. For comparison, Applied Materials' top-line growth was flat in the same quarter last year, while its adjusted earnings increased at a much slower pace of 5%. Applied Materials got 43% of its revenue from Chinese customers in the year-ago period. So, the company's growth accelerated even though restrictions on sales of advanced chipmaking equipment to Chinese customers hurt its business in its largest market abroad. This can be attributed to the global growth in semiconductor demand owing to catalysts such as artificial intelligence (AI). Equity research firm Summit Insights Group predicts that the improvement in demand for advanced chips in the second half of 2025 and next year should allow Applied Materials to continue doing well even if its Chinese business remains negatively impacted. Applied Materials CEO Gary Dickerson's remarks on last month's earnings conference call suggest something similar: The impact of AI datacenter innovation and investments is apparent in the wafer fab equipment market, where there are significant shifts in the spending mix this year. We see investment in leading edge foundry-logic growing substantially in 2025, and we also expect spending for leading-edge DRAM to be up significantly. Large-scale AI infrastructure investments such as the $500 billion Stargate project and the multibillion-dollar investments by cloud-computing giants to bolster their AI capabilities are the reasons why foundries and chipmakers are focused on enhancing their manufacturing capacities. Foundry giant Taiwan Semiconductor Manufacturing (NYSE: TSM), for instance, is set to increase its capital expenditures (capex) by 38% at the midpoint of its forecast to $40 billion in 2025. The Taiwan-based company is on track to build nine fabrication plants this year. TSMC further points out that it will spend 70% of its capital spending on advanced process nodes. That's not surprising as almost three-fourths of the company's revenue comes from selling chips manufactured using advanced nodes that are 7-nanometer (nm) or smaller in size. Looking ahead, TSMC estimates that its revenue from sales of AI chips is likely to increase at an annual rate of mid-40% through 2029. So, it won't be surprising to see the company spending more money on shoring up the production capacity of advanced chips to meet the AI-fueled demand. The increase in capex by the likes of TSMC is expected to drive a 2% increase in global semiconductor equipment spending this year to $110 billion, followed by a much stronger increase of 18% in 2026. This should ideally lead to an acceleration in Applied Materials' growth as well, paving the way for more stock price upside. Analysts are forecasting a 10% increase in Applied Materials' earnings this fiscal year to $9.49 per share. This is expected to be followed by a smaller jump in fiscal 2026 before another year of double-digit growth in fiscal 2027. However, the sharp acceleration in global semiconductor equipment spending could allow Applied Materials to grow at a faster rate over the next couple of years. But even if the company's bottom line grows in line with consensus expectations and its earnings hit $11.17 per share after a couple of fiscal years (as per the chart above), its stock price could jump to $329 (based on the tech-laden Nasdaq-100 index's forward earnings multiple of 29). That points toward an 88% gain from current levels in the next three years. Applied Materials stock is now trading at just 18 times forward earnings, which is a nice discount to the Nasdaq-100 index, which serves as a proxy for tech stocks. However, the market could reward Applied Materials with a richer earnings multiple in the future if it can deliver stronger-than-expected earnings growth. That's why savvy investors may want to buy this semiconductor stock while it is still trading at an incredibly cheap valuation, as it has the ability to go on a terrific bull run going forward. Before you buy stock in Applied Materials, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Materials wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Applied Materials and Taiwan Semiconductor Manufacturing. The Motley Fool has a disclosure policy. 1 Soaring Growth Stock to Buy Hand Over Fist Before It Is Too Late was originally published by The Motley Fool Sign in to access your portfolio

Yahoo

an hour ago

• Yahoo

Wells Fargo Upgrades Zscaler (ZS) Stock, Lifts PT

Zscaler, Inc. (NASDAQ:ZS) is one of the 10 software stocks analysts are upgrading. On June 13, Wells Fargo upgraded the company's stock to 'Overweight' from 'Equal Weight,' lifting the price objective to $385 from the previous target of $260. As per the firm, software infrastructure spending in H2 2025 is expected to be driven by the adoption of agentic AI, which tends to benefit several software companies, including Zscaler, Inc. (NASDAQ:ZS). An employee standing in front of a large data center, looking toward the future of cloud security. The research firm cited Zscaler, Inc. (NASDAQ:ZS)'s potential to reach $5 billion in annual recurring revenue by fiscal 2027 as one of the measures of the upgrade. Despite the increase in the stock price YTD, the firm believes it still possesses significant room for multiple expansion. Well Fargo expects more than 20% billings growth in FY 2026 and continues to see margin expansion continuing, together with revenue growth. Notably, the company's stock has increased by ~66% on a YTD basis. In May 2025, Zscaler, Inc. (NASDAQ:ZS) signed a definitive agreement to acquire Red Canary, which is a leading managed detection and response (MDR) vendor. Through the combination of Zscaler, Inc. (NASDAQ:ZS)'s high-volume and high-quality data with Red Canary's domain expertise in MDR, Zscaler, Inc. (NASDAQ:ZS) plans to ramp up its vision to deliver AI-powered security operations. While we acknowledge the potential of ZS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ZS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. Sign in to access your portfolio